Bluejay Diagnostics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bluejay Diagnostics, Inc. (BJDX) on March 14, 2026. The report details a material definitive agreement and unregistered sales of equity securities involving the company's leadership and board members.
Key Financial Metrics
The filing reports the following specific financial data related to a private placement transaction:
- Transaction Type: Private Placement of Common Stock.
- Shares Issued: 62,500 shares.
- Price Per Share: $2.00.
- Total Gross Proceeds: $125,000.
- Closing Date: March 17, 2026.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics outside of this specific transaction.
Material Changes
The primary material change is the issuance of new equity to five specific purchasers: Neil Dey (CEO and Board Member), Donald Chase (Chair of the Board), Svetlana Dey, Douglas Wurth, and Fred Zeidman (Board Members). Each purchaser acquired 12,500 shares for their individual accounts. The securities were sold pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D without general solicitation.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard regulatory disclosures regarding the unregistered nature of the sale. The company has not agreed to provide registration rights for these securities.
Investor Verification Checklist
- Verify the dilution impact of the 62,500 newly issued shares on existing shareholders.
- Confirm the use of the $125,000 gross proceeds as disclosed in subsequent financial reports.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for any restrictive covenants or special terms.
- Monitor future filings for any registration rights agreements that may be negotiated later.